Soligenix Inc (SNGX)
NASDAQ:SNGX
Want to see SNGX full AI Analyst Report?
SNGX Stock Chart & Stats
$1.44
-$0.10(-2.65%)
At close: 4:00 PM EST
$1.44
-$0.10(-2.65%)
Day’s Range― - ―
52-Week Range$0.28 - $6.23
Previous CloseN/A
Volume55.16K
Average Volume (3M)1.34M
Market Cap
$6.06M
Enterprise Value-$1.70M
Total Cash (Recent Filing)$6.03M
Total Debt (Recent Filing)$330.66K
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 07, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding14,824,174
10 Day Avg. Volume1,437,898
30 Day Avg. Volume1,335,037
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit607.58
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$1.50Price Target Upside4.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Orphan & Biodefense FocusSoligenix’s emphasis on rare diseases and biodefense creates durable structural advantages: smaller, underserved patient populations (orphan pathways), regulatory incentives and potential premium pricing. This focus supports targeted development strategies and attractive partnership or government funding opportunities over months.
Material Leverage ReductionA marked reduction in debt materially lowers financial fixed costs and default risk, improving strategic flexibility. With leverage down, management has more optionality to pursue partnerships, licensing or M&A without immediate pressure from creditors, which supports longer-term capital planning.
Access To Government & Collaboration FundingReliance on government grants and collaborative agreements offers a persistent non-dilutive funding channel aligned with its biodefense and rare-disease programs. These arrangements can sustain R&D spend during clinical stages and enable progress without immediate product revenues for several months.
Bears Say
Phase 3 FLASH2 HaltedThe independent committee recommendation to halt FLASH2 for futility is a structural setback: it materially reduces the probability of HyBryte reaching approval and commercial launch, forces a pipeline reassessment, and likely increases reliance on alternative programs or strategic transactions to create value.
No Commercial Revenue & Persistent LossesThe company remains a pre-revenue clinical-stage biotech with repeated sizable net losses. Without product sales, ongoing R&D and operating costs must be funded externally; persistent negative margins reduce internal financing options and raise the likelihood of future dilution or asset sales over the medium term.
High Cash Burn Vs. Limited CashOperating cash burn near -$10.8M TTM versus limited reported cash (RelatedArticles notes ~ $5.9M) implies constrained runway absent new funding. This structural funding gap increases dependency on grants, partners, or financing and elevates execution risk for remaining programs and strategic options.
Soligenix News
SNGX FAQ
What was Soligenix Inc’s price range in the past 12 months?
Soligenix Inc lowest stock price was $0.28 and its highest was $6.23 in the past 12 months.
What is Soligenix Inc’s market cap?
Soligenix Inc’s market cap is $6.06M.
When is Soligenix Inc’s upcoming earnings report date?
Soligenix Inc’s upcoming earnings report date is Aug 07, 2026 which is in 78 days.
How were Soligenix Inc’s earnings last quarter?
Soligenix Inc released its earnings results on May 08, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.28.
Is Soligenix Inc overvalued?
According to Wall Street analysts Soligenix Inc’s price is currently Undervalued.
Does Soligenix Inc pay dividends?
Soligenix Inc does not currently pay dividends.
What is Soligenix Inc’s EPS estimate?
Soligenix Inc’s EPS estimate is -0.16.
How many shares outstanding does Soligenix Inc have?
Soligenix Inc has 14,824,174 shares outstanding.
What happened to Soligenix Inc’s price movement after its last earnings report?
Soligenix Inc reported an EPS of -$0.28 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.87%.
Which hedge fund is a major shareholder of Soligenix Inc?
Currently, no hedge funds are holding shares in SNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Soligenix Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
SNGX Stock 12 Month Forecast
Average Price Target
$1.50
▲(4.17% Upside)
Technical Analysis
Ownership Overview
2.62% Insiders
0.72% Mutual Funds
<0.01% Other Institutional Investors
96.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---